Morantel

As a broad-spectrum anthelmintic commonly used in veterinary clinical practice, morantel belongs to the pyrantel class of anthelmintics. It inhibits the cholinesterase activity in parasites, causing muscle paralysis and spasm of the worms, which are then naturally excreted from the body along with the intestinal peristalsis of the host. With the advantages of high efficiency and low toxicity, it is mainly used for the prevention and control of parasitic infections such as gastrointestinal nematodes and lung nematodes in livestock and poultry, as well as Ascaris suum and pinworms in pigs, covering mainstream breeding species such as pigs, cattle, sheep and poultry, and is one of the core drugs in the deworming program for large-scale breeding.

At present, the global market size of veterinary anthelmintic API is growing steadily, among which anthelmintic drugs account for nearly 35%. Morantel has no obvious cross-resistance with commonly used anthelmintics such as albendazole and ivermectin, so its annual market demand growth rate remains at around 6.8%. On the domestic supply side, local pharmaceutical enterprises are the main players, which already have large-scale production capacity. In addition to meeting the demand of the domestic breeding market, about 40% of their production capacity is exported to emerging animal husbandry markets such as Southeast Asia and South America. At present, this variety has not been included in the scope of centralized volume-based procurement of veterinary drugs, and the market-oriented competition is relatively sufficient.

The original developer of morantel is Pfizer Inc. of the United States, with the original brand name Rumatel. The core compound patent expired globally in 1989. The currently mainstream marketed dosage forms are oral tablets and premixes, with common specifications including 25mg/50mg tablets and 10% content premixes. The original preparation has been included in the FDA Reference Listed Drug Directory for Animal Drugs. Domestically, 4 enterprises have completed CDE registration of morantel API, all with the registration status of A, and another 12 veterinary preparation varieties containing morantel have been approved for marketing in China. (Data as of December 2024, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for morantel API. Most of the products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can fully support veterinary drug enterprises in API quality research, preparation stability study and registration declaration related work.